



IFW

PATENT  
Attorney Docket No.: CIT1360-3

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Duncan Odom Art Unit: 1645  
Application No.: 10/672,408 Examiner: A.M. Navarro  
Filed: September 26, 2003 Confirmation No.: 1838  
Title: CHIMERIC CELL-TARGETING PATHOGENIC ORGANISM AND  
METHOD OF THERAPEUTIC USE


MAIL STOP AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Sir:

Transmitted herewith for the above-identified application please find:

1. Information Disclosure Statement (2 pgs.);
2. Form PTO-1449 (1 pg. in duplicate);
3. International Search Report (3 pgs.);
4. Two (2) References and
5. Return Receipt Postcard.

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service with sufficient postage as first class mail on this date, <b>July 26, 2004</b> , in an envelope addressed to: MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Gregory P. Austin (Name of Person Mailing Paper)	
 (Signature)	July 26, 2004 (Date)

In re Application of:  
Duncan Odom  
Application No.: 10/672,408  
Filed: September 26, 2003  
Page 2

PATENT  
Attorney Docket No.: CIT1360-3

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement, because it is being filed prior to the mailing of a first office action on the merits of the above-identified application. However, if any fee is required, authorization is hereby given to charge the amount of any such fee, or credit any overpayment, to Deposit Account No. 50-1355. A duplicate copy of this transmittal letter is enclosed.

Respectfully submitted,

Date: July 26, 2004



Lisa A. Haile, J.D., Ph.D.  
Registration No. 38,347  
Telephone: (858) 677-1456  
Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP  
4365 Executive Drive, Suite 1100  
San Diego, California 92121-2133  
USPTO CUSTOMER NO. 28213



PATENT  
Attorney Docket No.: CIT1360-3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Duncan Odom  
Application No.: 10/672,408  
Filed: September 26, 2003  
Title: CHIMERIC CELL-TARGETING PATHOGENIC ORGANISM AND  
METHOD OF THERAPEUTIC USE

Art Unit: 1645  
Examiner: A.M. Navarro  
Confirmation No.: 1838


MAIL STOP AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. § 1.97, Applicant brings to the Examiner's attention the parent application, U.S. Serial No. 10/002,389, filed November 30, 2001, now Patent No. 6,638,756, which is relied upon for an earlier filing date under 35 U.S.C. § 120.

Applicant respectfully requests that the references supplied in compliance with 37 C.F.R. § 1.97 in the above-referenced parent application, as well as those cited during its examination, be made of record. Copies of the documents will be found in the above-referenced parent application. For the convenience of the Examiner, the references are listed on the attached Form PTO-1449. Two additional references also are listed on the attached Form PTO-1449 and copies of those references are enclosed herewith. The International Search Report issued for the counterpart International application also is enclosed herewith.

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service with sufficient postage as first class mail on this date, <b>July 26, 2004</b> , in an envelope addressed to: MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Gregory P. Austin (Name of Person Mailing Paper)	
 (Signature)	July 26, 2004 (Date)


In re Application of:  
Duncan Odom  
Application No.: 10/672,408  
Filed: September 26, 2003  
Page 2

PATENT  
Attorney Docket No.: CIT1360-3

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement, because it is being filed prior to the mailing of a first office action on the merits of the above-identified application. However, if any fee is required, authorization is hereby given to charge the amount of any such fee, or credit any overpayment, to Deposit Account No. 50-1355.

Respectfully submitted,

Date: July 26, 2004



---

Lisa A. Haile, J.D., Ph.D.  
Registration No. 38,347  
Telephone: (858) 677-1456  
Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP  
4365 Executive Drive, Suite 1100  
San Diego, California 92121-2133  
USPTO CUSTOMER NO. 28213

<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office	<b>Docket No.:</b> CIT1360-3	<b>Application No.:</b> 10/672,408
	<b>Applicants:</b> Duncan Odom	<b>Confirmation No.:</b> 1838
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Filing Date:</b> September 26, 2003	<b>Group Art Unit:</b> 1645

### U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA	6,083,751 A	07/04/2000	Feldhaus et al.	435	372.3	05/09/1996
	AB	6,346,411 B1	02/12/2002	Hostetter et al.	435	254.11	03/08/1999

### FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	AC	Calderone et al., "Adherence and Receptor Relationships of <i>Candida albicans</i> ", <i>Microbiol. Rev.</i> , 55(1):1-20 (1991)
	AD	Gale et al., "Linkage of Adhesion, Filamentous Growth, and Virulence in <i>Candida albicans</i> to a Single Gene, <i>INT1</i> ," <i>Science</i> , 279:1355-1358 (1998)
	AE	Moritz et al., "Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells," <i>Proc. Natl. Acad. Sci. USA</i> , 91:4318-4322 (1994)
	AF	Wels et al., "Biotechnological and gene therapeutic strategies in cancer treatment," <i>Gene</i> 159:73-80 (1995)
	AG	Sonneborn et al., "Control of White-Opaque Phenotypic Switching in <i>Candida albicans</i> by the Efg1p Morphogenetic Regulator", <i>Infect. Immun.</i> , 67(9):4655-4660 (1999)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449